CancerAppy
Novel cancer therapeutic drugs
At CancerAppy, we specialize in cancer research, dedicated to discovering and developing new therapeutic targets. Our proprietary artificial intelligence methodology allows us to accelerate advancements in more effective cancer treatments
Driving innovation in breakthrough oncology treatments.
With our deep expertise in oncology and AI, we analyze vast amounts of multimodal data using advanced AI algorithms. This allows us to identify new therapeutic targets, discover lead compounds, understand their mechanisms of action, and explore potential drug combinations. Our technology also enables the development of next-generation antibody-drug conjugates (ADCs), driving more precise and effective cancer treatments.

We work in the early stage of the Drug Discovery Value Chain.

Our R&D Pipeline
At CancerAppy, we use AI-driven drug discovery to develop new cancer therapies, including novel ADCs (antibody-drug conjugates). Our pipeline moves from target discovery to preclinical development, bringing innovative treatments closer to patients.
News
Latest news about CancerAppy…
HONG KONG INVEST – European Companies Roadshow
From 15th to 18th of May, our CEO and CMO will be attending various international events in Hong Kong introducing the latest advances of our...
MEET2WIN_23
Our CEO Luis Martín Ezama will be attending the #Meet2win23 event 11th and 12th of May, exposing the characteristics of our pipeline of new cancer...
Anglonordic 23 – London
April 20th. We are going to attend the 19th Annual Anglonordic Life Science Conference.Meet us to discuss face to face about our latest works: CA04...
Grant CPP2021-008597 funded by:

Grant TQ2020-011486 funded by:


Subvencionado por el CDTI

Somos cliente Enisa

